GPS2, G protein pathway suppressor 2, 2874

N. diseases: 25; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0028754
Disease: Obesity
Obesity
0.040 AlteredExpression disease BEFREE Because GPS2 expression is down-regulated in some humans with obese and type 2 diabetes, the macrophage GPS-2/ABC-A1 pathway could be altered and contribute to atherogenesis.-Huang, Z., Liang, N., Damdimopoulos, A., Fan, R., Treuter, E. G protein pathway suppressor 2 (GPS2) links inflammation and cholesterol efflux by controlling lipopolysaccharide-induced ATP-binding cassette transporter A1 expression in macrophages. 30153049 2019
CUI: C0028754
Disease: Obesity
Obesity
0.040 Biomarker disease BEFREE Here, we demonstrate that adipocyte hypertrophy is triggered by loss of the corepressor GPS2 during obesity. 30208320 2018
CUI: C0028754
Disease: Obesity
Obesity
0.040 Biomarker disease BEFREE In accordance with this role, we have shown that GPS2 presence in adipocytes modulates systemic metabolism by restricting the activation of insulin signaling during the fasted state, whereas in absence of GPS2, the adipose tissue is more efficient at lipid storage, and obesity becomes uncoupled from inflammation and insulin resistance. 28123943 2017
CUI: C0028754
Disease: Obesity
Obesity
0.040 Biomarker disease BEFREE By contrast, transplantation of GPS2-overexpressing bone marrow into two mouse models of obesity (ob/ob and diet-induced obesity) reduced inflammation and improved insulin sensitivity. 27270589 2016
Diabetes Mellitus, Non-Insulin-Dependent
0.020 Biomarker disease BEFREE Because GPS2 expression is down-regulated in some humans with obese and type 2 diabetes, the macrophage GPS-2/ABC-A1 pathway could be altered and contribute to atherogenesis.-Huang, Z., Liang, N., Damdimopoulos, A., Fan, R., Treuter, E. G protein pathway suppressor 2 (GPS2) links inflammation and cholesterol efflux by controlling lipopolysaccharide-induced ATP-binding cassette transporter A1 expression in macrophages. 30153049 2019
CUI: C0239981
Disease: Hypoalbuminemia
Hypoalbuminemia
0.020 Biomarker disease BEFREE Patients with both an elevated CRP (>10 mg/L) and hypoalbuminemia (<35 g/L) were given a GPS score of 2 (GPS2). 27984403 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.020 Biomarker group BEFREE In disease-free survival, GPS 2 (P=0.019), with a tumor number ≥3 (P=0.004), and positive portal or venous invasion (P=0.034) were independent predictors of cancer recurrence in multivariate analysis. 28693167 2017
Diabetes Mellitus, Non-Insulin-Dependent
0.020 Biomarker disease BEFREE Loss of the co-repressor GPS2 sensitizes macrophage activation upon metabolic stress induced by obesity and type 2 diabetes. 27270589 2016
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.020 Biomarker group BEFREE Conclusively, our results suggest that GPS2 may act as a tumor suppressor in LPS and serve as a potential prognosis marker for this disease. 27460081 2016
CUI: C0239981
Disease: Hypoalbuminemia
Hypoalbuminemia
0.020 Biomarker disease BEFREE Hypoalbuminemia (< or = 35 g/L) and GPS were predictive of toxicity; GPS 2 was predictive of increased grade 2/3 toxicity compared with patients with a GPS of 0 or 1 (P < .05). 18794066 2008
CUI: C0400966
Disease: Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
0.010 Biomarker disease BEFREE Collectively, our data suggest that the GPS2-PPARα partnership in hepatocytes coordinates the progression of NAFLD in mice and in humans and thus might be of therapeutic interest. 30975991 2019
CUI: C1258215
Disease: Ileus
Ileus
0.010 Biomarker disease BEFREE Multivariate analysis demonstrated that GPS 2 (odds ratio [OR] 3.352; 95% confidence interval [CI] 1.049-10.71; p = 0.041) and preoperative ileus (OR 7.405; 95% CI 2.386-22.98; p = 0.001) were independent factors predictive of conversion from laparoscopic to open surgery. 30046949 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.010 Biomarker disease BEFREE Hepatocyte-specific Gps2 knockout in mice alleviates the development of diet-induced steatosis and fibrosis and causes activation of lipid catabolic genes. 30975991 2019
CUI: C3241937
Disease: Nonalcoholic Steatohepatitis
Nonalcoholic Steatohepatitis
0.010 Biomarker disease BEFREE Here we demonstrate that G protein pathway suppressor 2 (GPS2), a subunit of the nuclear receptor corepressor (NCOR) and histone deacetylase 3 (HDAC3) complex, has a central role in these alterations and accelerates the progression of NAFLD towards non-alcoholic steatohepatitis (NASH). 30975991 2019
Intestinal obstruction co-occurrent and due to decreased peristalsis
0.010 Biomarker disease BEFREE Multivariate analysis demonstrated that GPS 2 (odds ratio [OR] 3.352; 95% confidence interval [CI] 1.049-10.71; p = 0.041) and preoperative ileus (OR 7.405; 95% CI 2.386-22.98; p = 0.001) were independent factors predictive of conversion from laparoscopic to open surgery. 30046949 2019
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease
0.010 AlteredExpression disease BEFREE Liver gene expression data from human patients reveal that Gps2 expression positively correlates with a NASH/fibrosis gene signature. 30975991 2019
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.010 GeneticVariation disease BEFREE Del(17p) CLL has a unique driver mutation profile, including NOTCH1 (15%), RPS15 (12%), DDX3X (8%), and GPS2 (6%). 27503198 2017
CUI: C0272302
Disease: Gray Platelet Syndrome
Gray Platelet Syndrome
0.010 Biomarker disease BEFREE For the assessment of systemic inflammatory response using the GPS, patients were classified into three groups: Patients with normal serum albumin (<3.5 g/dl) and normal serum C-reactive protein (CRP) (≤1.0 mg/dl) were classified as GPS 0 (n=76), those with low serum albumin (<3.5 g/dl) or elevated serum CRP (>1.0 mg/dl) were classified as GPS 1 (n=58), and those with low serum albumin (<3.5 g/dl) and elevated serum CRP (>1.0 mg/dl) were classified as GPS 2 (n=10). 28693167 2017
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion
0.010 Biomarker phenotype BEFREE In overall survival, GPS 1 (P=0.042), GPS 2 (P<0.001) and positive portal or venous invasion (P<0.001) were independent predictors of poor patient outcome according to multivariate analysis. 28693167 2017
CUI: C0023827
Disease: liposarcoma
liposarcoma
0.010 Biomarker disease BEFREE G protein pathway suppressor 2 (GPS2) acts as a tumor suppressor in liposarcoma. 27460081 2016
CUI: C0278608
Disease: Adult Liposarcoma
Adult Liposarcoma
0.010 Biomarker disease BEFREE G protein pathway suppressor 2 (GPS2) acts as a tumor suppressor in liposarcoma. 27460081 2016
CUI: C0279984
Disease: Childhood Liposarcoma
Childhood Liposarcoma
0.010 Biomarker disease BEFREE G protein pathway suppressor 2 (GPS2) acts as a tumor suppressor in liposarcoma. 27460081 2016
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.010 Biomarker disease BEFREE Isolated reports of individual rearrangements of GPS2 in a prostate carcinoma cell line and in glioblastoma multiforme, each with different partner genes, recently emerged from high-throughput sequencing studies but have not been further evaluated for biological effect. 25139254 2014
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.010 Biomarker disease BEFREE Isolated reports of individual rearrangements of GPS2 in a prostate carcinoma cell line and in glioblastoma multiforme, each with different partner genes, recently emerged from high-throughput sequencing studies but have not been further evaluated for biological effect. 25139254 2014
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.010 Biomarker disease BEFREE Isolated reports of individual rearrangements of GPS2 in a prostate carcinoma cell line and in glioblastoma multiforme, each with different partner genes, recently emerged from high-throughput sequencing studies but have not been further evaluated for biological effect. 25139254 2014